Related references
Note: Only part of the references are listed.Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
Elias Tayar et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2023)
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
Akatsuki Saito et al.
NATURE (2022)
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
Seth Toback et al.
LANCET RESPIRATORY MEDICINE (2022)
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study
Ruvim Izikson et al.
LANCET RESPIRATORY MEDICINE (2022)
Inhalable dry powder mRNA vaccines based on extracellular vesicles
Kristen D. Popowski et al.
MATTER (2022)
High prevalence of SARS-CoV-2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran
Seyed A. Hashemi et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Co-infection of influenza A virus and SARS-CoV-2: A retrospective cohort study
Yuan Cheng et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
Cyrielle Fougeroux et al.
NATURE COMMUNICATIONS (2021)
Coinfection with influenza A virus enhances SARS-CoV-2 infectivity
Lei Bai et al.
CELL RESEARCH (2021)
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
Rajeka Lazarus et al.
LANCET (2021)
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels et al.
NATURE MEDICINE (2021)
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Annette B. Vogel et al.
NATURE (2021)
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
Alexander Muik et al.
SCIENCE (2021)
Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
Hyon-Xhi Tan et al.
NATURE COMMUNICATIONS (2021)
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
Nikolaos C. Kyriakidis et al.
NPJ VACCINES (2021)
Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design
Julia Stowe et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2021)
Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates
Linling He et al.
SCIENCE ADVANCES (2021)
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Ugur Sahin et al.
NATURE (2021)
Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19
Zhenhua Li et al.
NATURE NANOTECHNOLOGY (2021)
Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
R. Glenn King et al.
VACCINES (2021)
Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study
Jillian H. Hurst et al.
CLINICAL INFECTIOUS DISEASES (2021)
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Petra Mlcochova et al.
NATURE (2021)
Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil
Guenther Fink et al.
BMJ EVIDENCE-BASED MEDICINE (2021)
Hospitality and tourism industry amid COVID-19 pandemic: Perspectives on challenges and learnings from India
Vikrant Kaushal et al.
INTERNATIONAL JOURNAL OF HOSPITALITY MANAGEMENT (2021)
Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study
Robertus van Aalst et al.
VACCINE (2020)
A novel coronavirus outbreak of global health concern
Chen Wang et al.
LANCET (2020)
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Qihui Wang et al.
CELL (2020)
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Wanbo Tai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Ning Wang et al.
FRONTIERS IN MICROBIOLOGY (2020)
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Abishek Chandrashekar et al.
SCIENCE (2020)
Development of an inactivated vaccine candidate for SARS-CoV-2
Qiang Gao et al.
SCIENCE (2020)
The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China
Qiang Ding et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
SARS-CoV-2 and influenza virus co-infection
Elena Cuadrado-Payan et al.
LANCET (2020)
Pathogenesis and transmission of SARS-CoV-2 in golden hamsters
Sin Fun Sia et al.
NATURE (2020)
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
Lianpan Dai et al.
CELL (2020)
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Dorottya Laczko et al.
IMMUNITY (2020)
Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs
Jesus Zepeda-Cervantes et al.
FRONTIERS IN IMMUNOLOGY (2020)
Engineering Antiviral Vaccines
Xingwu Zhou et al.
ACS NANO (2020)
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Luca Piccoli et al.
CELL (2020)
Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques
Malika Aid et al.
CELL (2020)
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Philip J. M. Brouwer et al.
SCIENCE (2020)
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Lisa H. Tostanoski et al.
NATURE MEDICINE (2020)
A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge
Yfat Yahalom-Ronen et al.
NATURE COMMUNICATIONS (2020)
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
Yixuan J. Hou et al.
SCIENCE (2020)
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Alexandra C. Walls et al.
CELL (2020)
Co-infection with SARS-CoV-2 and influenza A virus
Shuhei Azekawa et al.
IDCASES (2020)
Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15
James G. Donahue et al.
VACCINE (2019)
Influenza vaccine: Where are we and where do we go?
Mohsen Keshavarz et al.
REVIEWS IN MEDICAL VIROLOGY (2019)
Live attenuated influenza vaccine use and safety in children and adults with asthma
Jonathan Duffy et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2017)
Brucella abortus S19 and RB51 vaccine immunogenicity test: Evaluation of three mice (BALB/c, Swiss and CD-1®) and two challenge strains (544 and 2308)
Karina Leite Miranda et al.
VACCINE (2015)
The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes
Changhui Fu et al.
BIOMATERIALS (2013)
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Martin A. Maier et al.
MOLECULAR THERAPY (2013)
Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes
Ashley L. St. John et al.
NATURE MATERIALS (2012)
Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans
Rebecca J. Garten et al.
SCIENCE (2009)
Antibody quantity versus quality after influenza vaccination
JingQi Feng et al.
VACCINE (2009)
Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections
Shai Ashkenazi et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2006)